ENTREPRENEURSHIP ARTICLES
-
Beyond RAG: When To Use Semantics, Retrieval, Graph, And Agent Inference
Most large pharmaceutical organizations already own many of the components required for layered architecture. The problem is that these systems often evolve independently.
-
Beyond RAG: Why Life Sciences AI Workflows Need Better Context, Not Just Better Models
Teams want AI systems that can answer complex scientific questions across value chain, but as these systems move closer to production, a recurring problem is becoming visible.
-
A Quantitative Procurement Framework For Scaling Organ-On-A-Chip Adoption Across Markets Of Varying Maturity
OoC commercialization is moving beyond technical feasibility toward reproducible, scalable, and economically viable adoption. Achieving this shift requires procurement to move beyond unit-price negotiations.
-
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
A Procurement Framework For Evaluating Innovation Across Pharma R&D Suppliers
The patent cliff has changed the mandate of R&D procurement. This paper introduces a 100-point innovation partner assessment framework that scores R&D suppliers.
-
2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.
-
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
-
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
-
2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.
-
2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.